Low or very low confidence in evidence for reduced pain intensity after treatment with various meds, med combos
News and Features
Participants with lower bone mineral density at femoral neck more likely to develop all-cause dementia, Alzheimer disease during follow-up.
The DISSOLVE I and II trials evaluated the efficacy and safety of 2 different dose levels of SEL-212 in adults 19 years of age and older with chronic refractory gout.
The approval of the new citrate-free, high-concentration formulation was based on data from a phase 1 pharmacokinetics bridging study.
Pulmonary function tests may be beneficial every six months, may be of use in initiating noninvasive ventilation when indicated
Some clinically meaningful improvements seen compared with education or inactive control
No improvement seen in lower back pain with acetaminophen alone or placebo across trials
Latest findings are from a post hoc meta-analysis of pooled data from the DAPA-HF and DELIVER trials.
Plasma D-dimer had comparable accuracy to CRP, ESR, fibrinogen for diagnosing periprosthetic joint infection in patients with revision hip or knee arthroplasty
The Company is currently evaluating the efficacy and safety of taldefgrobep alfa in patients with SMA in the phase 3 RESILIENT study.
Belimumab is a B-lymphocyte stimulator-specific inhibitor.
A new dosing regimen for Turalio® (pexidartinib) is now available for the treatment of adults with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery. The recommended dose of Turalio is now 250mg orally twice daily (taken as two 125mg capsules) with a low-fat meal…
High-dose therapy is not superior for most outcomes, except for the Knee Injury and Osteoarthritis Outcome Score for function in sports and recreation
No significant difference seen in incidence of death, deep vein thrombosis, pulmonary embolism, bleeding complications
AOC 1020 is designed to reduce the expression of DUX4 mRNA and DUX4 protein in muscles.